mitoxantrone has been researched along with Hormone-Dependent Neoplasms in 22 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the use of docetaxel 75 mg/m(2) intravenously every 3 weeks plus prednisone 5 mg orally twice daily in men with metastatic hormone-refractory prostate cancer (HRPC) progressing after first-line mitoxantrone/prednisone (MP), the primary outcome being progression-free survival with prostatic-specific antigen (PSA) and pain response, toxicity and quality of life (QoL) also assessed." | 5.13 | The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. ( Cheng, T; Ernst, S; Karakiewicz, P; North, S; Perrotte, P; Ruether, D; Saad, F; Winquist, E, 2008) |
| "The present randomized phase III trial was designed to detect a 15% benefit in relapse-free survival (RFS) or overall survival (OS) from the incorporation of adjuvant tamoxifen to the combination of CNF [cyclophosphamide, 500 mg/m2; mitoxantrone (Novantrone), 10 mg/m2; fluorouracil, 500 mg/m2 chemotherapy and ovarian ablation in premenopausal patients with node-positive breast cancer and conversely from the incorporation of CNF chemotherapy to adjuvant tamoxifen in node-positive postmenopausal patients." | 5.11 | Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study. ( Adamou, A; Bafaloukos, D; Ekonomopoulos, T; Fountzilas, G; Georgoulias, V; Kalofonos, HP; Klouvas, G; Kosmidis, P; Koukouras, D; Kouvatseas, G; Kyriakou, K; Pavlidis, N; Pectasidis, D; Polychronis, A; Razis, E; Samantas, E; Skarlos, D; Stathopoulos, G; Zamboglou, N; Zombolas, V, 2004) |
| "The average treatment levels of pain did not differ, hence, the average mediated effect of treatment on GHRQL was zero." | 2.74 | Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial. ( Donaldson, GW; Moinpour, CM; Nakamura, Y, 2009) |
| "Mitoxantrone has activity similar to that of doxorubicin, is less cardiotoxic, and is widely used to treat prostate cancer." | 2.72 | Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer. ( Bergan, RC; Eklund, J; Gallot, L; Jovanovic, B; Kozloff, M; Mariott, M; Pins, M; Robin, E; Schilder, L; Starr, A; Vlamakis, J, 2006) |
| "Docetaxel, a taxane previously approved for the treatment of breast cancer and non-small cell lung cancer, was approved by the United States Food and Drug Administration on May 19, 2004 for use in combination with prednisone for the treatment of metastatic androgen-independent (hormone-refractory) prostate cancer." | 2.71 | Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. ( Abraham, S; Dagher, R; Li, N; Pazdur, R; Rahman, A; Sridhara, R, 2004) |
| "The management of metastatic prostate cancer that has relapsed after initial hormonal manipulation remains a major problem, with the majority of patients dying within 12 months." | 2.68 | Management of hormone-resistant prostate cancer: an Australian trial. ( Coorey, G; Farebrother, T; Page, J; Raghavan, D; Rosen, M, 1996) |
| " When given with prednisone, docetaxel was also shown to reduce pain and serum prostate specific antigen levels and improve quality of life compared with mitoxantrone/prednisone." | 2.43 | Which drug combination for hormone-refractory prostate cancer? ( Doggrell, SA, 2005) |
| "In the United States, prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in men." | 2.40 | Chemotherapy in advanced prostate cancer. ( Beedassy, A; Cardi, G, 1999) |
| "The treatment of hormonally resistant prostate cancer is therefore palliative." | 2.39 | Overview of Canadian trials in hormonally resistant prostate cancer. ( Moore, MJ; Tannock, IF, 1996) |
| "Men with androgen-independent prostate cancer were randomly assigned to either docetaxel/estramustine (D/E) or mitoxantrone/prednisone (M/P) treatment on Southwest Oncology Group Protocol 99-16." | 1.33 | Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. ( Ankerst, DP; Benson, MC; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, JA; Kohli, M; Lara, PN; Petrylak, DP; Raghavan, D; Small, EJ; Tangen, CM; Taplin, ME, 2006) |
| "For 13 (93%) of them, circulating tumor cells were detectable during the time of PSA response, i." | 1.32 | Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy. ( Bilkenroth, U; Froehner, M; Fuessel, S; Kraemer, K; Linné, C; Meye, A; Schmidt, U; Wirth, MP, 2004) |
| "Hormone-refractory prostate cancer is the terminal step in the natural history of prostate cancer." | 1.30 | Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. ( Crawford, D; Fisher, E; Hussain, M; Petrylak, D; Tangen, C, 1999) |
| "Patients with early breast cancer (T1/T2) had a complete clinical resolution in 41% (16/39) of cases after MMM and in 20% (7/35) of cases following endocrine therapy compared with 14% (2/14) advanced tumours (T3/T4) following MMM and (0/12) following endocrine therapy." | 1.29 | Assesssment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer. ( Coombes, RC; Corbishley, C; Ford, HT; Gazet, JC; Griffin, M; Lowndes, S; Makinde, V; Quilliam, J; Sutcliffe, R, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (27.27) | 18.2507 |
| 2000's | 15 (68.18) | 29.6817 |
| 2010's | 1 (4.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saad, F | 1 |
| Ruether, D | 1 |
| Ernst, S | 1 |
| North, S | 1 |
| Cheng, T | 1 |
| Perrotte, P | 1 |
| Karakiewicz, P | 1 |
| Winquist, E | 1 |
| Moinpour, CM | 1 |
| Donaldson, GW | 1 |
| Nakamura, Y | 1 |
| Eisenberger, MA | 1 |
| Antonarakis, ES | 1 |
| Fountzilas, G | 1 |
| Stathopoulos, G | 1 |
| Kouvatseas, G | 1 |
| Polychronis, A | 1 |
| Klouvas, G | 1 |
| Samantas, E | 1 |
| Zamboglou, N | 1 |
| Kyriakou, K | 1 |
| Adamou, A | 1 |
| Pectasidis, D | 1 |
| Ekonomopoulos, T | 1 |
| Kalofonos, HP | 1 |
| Bafaloukos, D | 1 |
| Georgoulias, V | 1 |
| Razis, E | 1 |
| Koukouras, D | 1 |
| Zombolas, V | 1 |
| Kosmidis, P | 1 |
| Skarlos, D | 1 |
| Pavlidis, N | 1 |
| Schmidt, U | 1 |
| Bilkenroth, U | 1 |
| Linné, C | 1 |
| Fuessel, S | 1 |
| Kraemer, K | 1 |
| Froehner, M | 1 |
| Wirth, MP | 1 |
| Meye, A | 1 |
| Dagher, R | 1 |
| Li, N | 1 |
| Abraham, S | 1 |
| Rahman, A | 1 |
| Sridhara, R | 1 |
| Pazdur, R | 1 |
| Itoh, N | 1 |
| Oudard, S | 1 |
| Banu, E | 1 |
| Beuzeboc, P | 1 |
| Voog, E | 1 |
| Dourthe, LM | 1 |
| Hardy-Bessard, AC | 1 |
| Linassier, C | 1 |
| Scotté, F | 1 |
| Banu, A | 1 |
| Coscas, Y | 1 |
| Guinet, F | 1 |
| Poupon, MF | 1 |
| Andrieu, JM | 1 |
| Cabrespine, A | 1 |
| Bay, JO | 1 |
| Barthomeuf, C | 1 |
| Curé, H | 1 |
| Chollet, P | 1 |
| Debiton, E | 1 |
| Doggrell, SA | 1 |
| Joshua, AM | 1 |
| Nordman, I | 1 |
| Venkataswaran, R | 1 |
| Clarke, S | 1 |
| Stockler, MR | 1 |
| Boyer, MJ | 1 |
| Eklund, J | 1 |
| Kozloff, M | 1 |
| Vlamakis, J | 1 |
| Starr, A | 1 |
| Mariott, M | 1 |
| Gallot, L | 1 |
| Jovanovic, B | 1 |
| Schilder, L | 1 |
| Robin, E | 1 |
| Pins, M | 1 |
| Bergan, RC | 1 |
| Petrylak, DP | 1 |
| Ankerst, DP | 1 |
| Jiang, CS | 1 |
| Tangen, CM | 1 |
| Hussain, MH | 2 |
| Lara, PN | 1 |
| Jones, JA | 1 |
| Taplin, ME | 1 |
| Burch, PA | 1 |
| Kohli, M | 1 |
| Benson, MC | 1 |
| Small, EJ | 2 |
| Raghavan, D | 2 |
| Crawford, ED | 1 |
| Rosenberg, JE | 1 |
| Weinberg, VK | 1 |
| Kelly, WK | 1 |
| Michaelson, D | 1 |
| Wilding, G | 1 |
| Gross, M | 1 |
| Hutcheon, D | 1 |
| Mimeault, M | 1 |
| Mehta, PP | 1 |
| Hauke, R | 1 |
| Henichart, JP | 1 |
| Depreux, P | 1 |
| Lin, MF | 1 |
| Batra, SK | 1 |
| Gazet, JC | 1 |
| Coombes, RC | 1 |
| Ford, HT | 1 |
| Griffin, M | 1 |
| Corbishley, C | 1 |
| Makinde, V | 1 |
| Lowndes, S | 1 |
| Quilliam, J | 1 |
| Sutcliffe, R | 1 |
| Moore, MJ | 2 |
| Tannock, IF | 1 |
| Coorey, G | 1 |
| Rosen, M | 1 |
| Page, J | 1 |
| Farebrother, T | 1 |
| Siu, LL | 1 |
| Beedassy, A | 1 |
| Cardi, G | 1 |
| Hussain, M | 1 |
| Petrylak, D | 1 |
| Fisher, E | 1 |
| Tangen, C | 1 |
| Crawford, D | 1 |
| Heicappell, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer[NCT00004001] | Phase 3 | 770 participants (Actual) | Interventional | 1999-10-31 | Completed | ||
| A Phase I Trial of Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer (CRPC)[NCT03737370] | Phase 1 | 25 participants (Anticipated) | Interventional | 2018-01-30 | Recruiting | ||
| A Phase II Study of AZD2171 in Metastatic Androgen Independent Prostate Cancer[NCT00436956] | Phase 2 | 59 participants (Actual) | Interventional | 2006-10-16 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Time from treatment start date until date of death or date last known alive. (NCT00436956)
Timeframe: 44 months
| Intervention | Months (Median) |
|---|---|
| 20 mg AZD2171 Daily | 11.7 |
| 20 mg AZD2171 + 10mg Prednisone Daily | 9.9 |
Time interval from start of treatment to documented evidence of disease progression. (NCT00436956)
Timeframe: up to 14.9 months based on a Kaplan-Meier analysis.
| Intervention | Months (Median) |
|---|---|
| 20 mg AZD2171 Daily | 3.6 |
| 20 mg AZD2171 + 10mg Prednisone Daily | 3.7 |
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00436956)
Timeframe: Date treatment consent signed to date off study, approximately 61.5 months
| Intervention | Participants (Count of Participants) |
|---|---|
| All Participants- AZD2171 & Prednisone | 59 |
PFS is the proportion of subjects who progress or die by 6 months after the start of the combined therapy. PFS is determined by prostatic specific antigen (PSA) consensus criteria and the Response Evaluation Criteria in Solid Tumors (RECIST). PSA consensus criteria is defined as PSA decline of >/= 50% or PSA progression. RECIST is defined as the following: Complete response (CR) is disappearance of all target lesions; partial response (PR) is at least a 30% decline in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD; and stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease ((PD) at least a 20% increase in the sum of the LD of target lesions, or the appearance of one or more lesions), taking as reference the smallest sum LD since the treatment started. Data is estimated and the probability of PFS as a function of time was determined using the Kaplan-Meier method. (NCT00436956)
Timeframe: 6 months
| Intervention | percent probability (Number) |
|---|---|
| All Participants - AZD2171 & Prednisone | 43.9 |
Here is the number of Grade 2 (moderate) toxicities. (NCT00436956)
Timeframe: 61.5 months
| Intervention | toxicities (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hypertension | Fatigue | Anorexia | Weight loss | Hypothyroidism | Dehydration | Prolonged QTc | Nausea | Diarrhea | Hypoalbuminemia | Proteinuria | Elevated alkaline phosphatase | Aspartate transaminase | Vomiting | Hyperbilirubinemia | Muscle weakness | |
| 20 mg AZD2171 + 10mg Prednisone Daily | 8 | 4 | 6 | 4 | 6 | 2 | 2 | 3 | 0 | 3 | 3 | 2 | 3 | 2 | 1 | 1 |
| 20 mg AZD2171 Daily | 17 | 15 | 12 | 11 | 7 | 8 | 8 | 7 | 8 | 5 | 5 | 4 | 3 | 4 | 4 | 2 |
Here is the number of Grade 3 (severe) toxicities. (NCT00436956)
Timeframe: 61.5 months
| Intervention | toxicities (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hypertension | Fatigue | Anorexia | Weight loss | Hypothyroidism | Dehydration | Prolonged QTc | Nausea | Diarrhea | Hypoalbuminemia | Proteinuria | Elevated alkaline phosphatase | Aspartate transaminase | Vomiting | Hyperbilirubinemia | Muscle weakness | |
| 20 mg AZD2171 + 10mg Prednisone Daily | 0 | 2 | 1 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 20 mg AZD2171 Daily | 0 | 4 | 1 | 2 | 0 | 3 | 1 | 1 | 0 | 0 | 0 | 5 | 2 | 1 | 1 | 3 |
Response was evaluated by the RECIST. Complete response (CR) is disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Progressive disease (PD)is at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. (NCT00436956)
Timeframe: Every 2 cycles (approximately 56 days)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response | Confirmed Partial Response | Unconfirmed Partial Response | Not Evaluable | |
| All Participants - AZD2171 & Prednisone | 0 | 6 | 1 | 1 |
6 reviews available for mitoxantrone and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
[Chemotherapy for prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bridged-Ring Compo | 2005 |
Which drug combination for hormone-refractory prostate cancer?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramus | 2005 |
Overview of Canadian trials in hormonally resistant prostate cancer.
Topics: Antineoplastic Agents; Canada; Clinical Trials as Topic; Humans; Male; Mitoxantrone; Neoplasms, Horm | 1996 |
Other chemotherapy regimens including mitoxantrone and suramin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyc | 1997 |
Chemotherapy in advanced prostate cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Clinical | 1999 |
Controversies in chemotherapy of prostate cancer.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgen Antagonists; Antigens, Neoplasm; Antineoplastic Ag | 2002 |
9 trials available for mitoxantrone and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; | 2008 |
Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; | 2009 |
Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 2004 |
Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2005 |
Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relat | 2005 |
Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Ketoconazole; Male; | 2006 |
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over | 2007 |
Management of hormone-resistant prostate cancer: an Australian trial.
Topics: Aged; Antineoplastic Agents; Humans; Male; Middle Aged; Mitoxantrone; Neoplasms, Hormone-Dependent; | 1996 |
7 other studies available for mitoxantrone and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cytotoxins; Disease Progression; Docetaxel; | 2012 |
Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Estramustin | 2004 |
In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment.
Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Benzophenanthridines; Carboplatin; Drug A | 2005 |
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexameth | 2006 |
Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Synergism; ErbB | 2007 |
Assesssment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer.
Topics: Adult; Aged; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic | 1996 |
Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; | 1999 |